Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000558

Drug Information
NameTacrine
Synonyms1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; NCGC00024908-04; 321-64-2; Acridine, 1,2,3,4-tetrahydro-9-amino-; Tetrahydroaminacrine; AKOS000277493; 1,2,3,4-tetrahydroacridin-9-amine; AC1Q51C5; HMS2089F19; AC1L1CK0; EU-0010966; AB00053524; BIDD:GT0090; Tacrinum [INN-Latin]; BAS 00232275; CS 12602; D08555; Tacrina [INN-Spanish]; BSPBio_000337; Tacrine hydrochloride; NCIOpen2_003667; Tetrahydroaminocrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); NCGC00024908-05; Prestwick1_000329; 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; CPD-10887; C01453; Tacrina; BRD-K81473089-003-03-0; 1mx1; BSPBio_003298; Prestwick3_000329; Lopac0_000036; Tocris-0965; CID1935; STK101308; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-amino-1,2,3,4-tetrahydroacridine; ZINC19014866; Prestwick2_000329; KBio3_002518; KBio2_000896; BRN 0147610; Spectrum_000416; Tacrine (INN); BPBio1_000371; Spectrum4_000819; Spectrum3_001709; NCGC00015054-01; KBioSS_000896; Prestwick0_000329; nchembio.188-comp31; 1,2,3,4-Tetrahydro-acridin-9-ylamine; FT-0083001; Lopac-A-3773; PDSP1_000330; CHEBI:45980; KBio2_006032; Tacrinum; UNII-4VX7YNB537; KBioGR_001337; BRD-K81473089-003-04-8; MLS000758202; 2aox; BBL001044; SPBio_002258; NCGC00024908-01; CHEMBL95; Spectrum5_001402; DB00382; Spectrum2_001812; EINECS 206-291-2; Tacrine [INN:BAN]; SPBio_001823; Tacrinal; Tacrinal (TN); Oprea1_008681; Romotal; Cognex; NINDS_000936; KBio2_003464; 1,2,3,4-Tetrahydroaminoacridine; NCGC00024908-03; LS-1191; ST083243; Tetrahydroaminocrin; 1,2,3,4-Tetrahydro-9-acridineamine; 9-Acridinamine, 1,2,3,4-tetrahydro-; NCGC00015054-07; DivK1c_000936; 2aow; PDSP2_000328; C13H14N2; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); nchembio.2007.55-comp2; Tetrahydroaminoacridine; MolPort-000-881-472; Tacrine; IDI1_000936; tha; KBio1_000936; 9-AMINOTETRAHYDROACRIDINE; Tenakrin; 1684-40-8 (hydrochloride)
Trade NameCognex
IndicationAlzheimer's disease
[ICD9: 331.0   ICD10: G30]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7
H,2,4,6,8H2,(H2,14,15)
InChIKeyYLJREFDVOIBQDA-UHFFFAOYSA-N
Canonical SMILESC1CCC2=NC3=CC=CC=C3C(=C2C1)N    
Therapeutic ClassParasympathomimetics
CAS NumberCAS 321-64-2
FormulaC13H14N2
PubChem Compound IDCID 1935.
PubChem Substance IDSID 4630.
ChEBI45980;
SuperDrug ATC IDN06DA01
SuperDrug CAS ID000321642;
TargetAcetylcholinesteraseInhibitor[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543